- Komplexní alely genu CFTR v éře CFTR modulátorů2023 | 2. lékařská fakulta, Lékařská fakulta v Plzni, 1. lékařská fakulta
- Availability of CFTR modulators in countries of Eastern Europe: The reality in 20222022 | 2. lékařská fakulta
- Building global development strategies for cf therapeutics during a transitional cftr modulator era2020 | 2. lékařská fakulta
- Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view2020 | 2. lékařská fakulta
- Modulátory CFTR proteinu2019 | 2. lékařská fakulta
- Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells2021 | 2. lékařská fakulta
- Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations2019 | 2. lékařská fakulta
- Aktuální možnosti kauzální terapie cystické fibrózy v dětském věku2021 | Lékařská fakulta v Plzni
- Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A > G2020 | 2. lékařská fakulta
- Nové možnosti terapie cystické fibrózy +12020 | 2. lékařská fakulta
- CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials2019 | 2. lékařská fakulta
- Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery2019 | 2. lékařská fakulta
- Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry2021 | 2. lékařská fakulta
- Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination2023 | 2. lékařská fakulta
- Nové možnosti léčby cystické fibrózy2023 | 2. lékařská fakulta
- GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)2019 | 2. lékařská fakulta
- Kauzální léčba cystické fibrózy2019 | 2. lékařská fakulta
- Correction of CFTR function in intestinal organoids to guide treatment of Cystic Fibrosis2021 | 2. lékařská fakulta
- Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment2019 | 2. lékařská fakulta
- Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis2022 | 2. lékařská fakulta
- Health-economic aspects of cystic fibrosis screening and therapy2014 | 2. lékařská fakulta
- Standards for the care of people with cystic fibrosis; establishing and maintaining health2024 | 2. lékařská fakulta
- Laboratory biomarkers for lung disease severity and progression in cystic fibrosis2020 | 2. lékařská fakulta
- Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues2024 | 2. lékařská fakulta, Ústřední knihovna
- Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis2022 | 2. lékařská fakulta
- Mutant CFTR Drives TWIST1 mediated epithelial-mesenchymal transition2020 | 2. lékařská fakulta
- Case report of two adults with F508del/3849+10 kb C > T genotype regaining exocrine pancreatic function following treatment with elexacaftor/tezacaftor/ivacaftorPublikace bez příslušnosti k fakultě
- Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele2019 | 2. lékařská fakulta